Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Genetic Predisposition to Liking Amphetamine Reduces Risk of Schizophrenia and ADHD

08.04.2014

Genetic variants associated with enjoying the effects of d-amphetamine—the active ingredient in Adderall—are also associated with a reduced risk for developing schizophrenia and attention deficit hyperactivity disorder (ADHD), report scientists from the University of Chicago in the Proceedings of the National Academy of Sciences on April 7. The results support a long-standing hypothesis that dopamine, the neurotransmitter connected with the euphoric effects of amphetamine, is related to schizophrenia and ADHD.

“Some of the variants that make you like amphetamine also appear to make you less likely to develop schizophrenia and ADHD,” said study leader Abraham Palmer, PhD, associate professor of human genetics at the University of Chicago. “Our study provides new insights into the biology of amphetamine and how it relates to the biology of risk for these psychiatric diseases.”

Palmer and his team previously conducted a genome-wide association study (GWAS) to identify genetic variants associated with experiencing the euphoric effects of amphetamine, which is thought to affect risk for drug abuse. Almost 400 volunteers were given d-amphetamine in a double-blind, placebo-controlled experiment.

They were then asked to report how the drug made them feel using carefully designed questionnaires. The researchers measured genetic differences between these subjects at approximately a million sites throughout the genome to identify variations in the DNA code known as single nucleotide polymorphisms, or SNPs. They assessed the relationships between each of these SNPs and sensitivity to amphetamine.

Using data from other large-scale GWAS studies, the team examined these same SNPs for possible overlapping associations with psychiatric disorders. Through rigorous statistical testing they found that an unexpectedly large number of SNPs were associated with both sensitivity to amphetamine and risk of developing schizophrenia or ADHD. This suggested that these traits are influenced by a common set of genetic variants.
Moreover, a significant proportion of this observed overlap appeared to be caused by variants that increased enjoyment of the effects of amphetamine but decreased the risk for both psychiatric diseases.

The researchers performed similar analyses for traits that were not expected to be related to amphetamine sensitivity, such as height, irritable bowel disease and Parkinson’s disease. In all of these cases they observed no more overlapping SNPs than would have been expected by chance alone.

“While this approach would not be a useful diagnostic test, we expect that people who like the effects of amphetamine would be slightly less likely to develop schizophrenia and ADHD,” Palmer said. “And people who did not like amphetamine, we would predict, are slightly more likely to develop these diseases.”

“What is particularly striking is that by examining people’s responses for just a few hours after taking a drug, we can identify an underlying genetic propensity that can manifest as a psychiatric disease over the course of a lifetime,” he adds.

These results provide unique genetic evidence for the role of dopamine in schizophrenia and ADHD. Schizophrenia is commonly treated using drugs that block dopamine signaling, while ADHD is treated using drugs, including d-amphetamine itself, that enhance dopamine signaling. Despite opposite treatments, amphetamine-liking SNPs reduced the risk for developing both diseases, suggesting that dopamine’s role is more complex than hypothesized.

The study also offers a new direction for the analysis of a wide range of similar genetic studies, particularly ones with smaller sample sizes. By analyzing the results of those studies for overlap with data from much larger genetic studies, promising genetic variants that would otherwise never stand out among the noise of hundreds of thousands of other random variants can be identified.

“Our approach offers a promising new direction for studying complex psychiatric behaviors using the whole-genome approach,” said co-author Harriet de Wit, PhD, professor of psychiatry and behavioral neuroscience at the University of Chicago.
The team plans to further study the SNPs identified in this study for their functional roles in amphetamine liking, schizophrenia and ADHD. In addition, Palmer hopes to explore genetic predispositions toward liking or disliking other therapeutic drugs and whether sensitivity to those drugs might also overlap with the diseases for which these drugs are used.

“When we use a drug treatment, we know exactly what systems have been perturbed,” Palmer said. “So when we see overlap for alleles that affect how you respond to drugs and a disease, we can hone in on what those alleles are doing biologically. This is instrumental for translating those results into new treatments and cures, which is the ultimate reason for performing genetic studies of disease.”

The study, “Genetic variation associated with euphorigenic effects of d-amphetamine is associated with diminished risk for schizophrenia and attention deficit hyperactivity disorder,” was supported by the National Institutes of Health. Additional authors include Amy B. Hart, Eric R. Gamazon, Barbara E. Engelhardt, Pamela Sklar, Anna K. Kähler, Christina M. Hultman, Patrick F. Sullivan, Benjamin M. Neale, Stephen V. Faraone, Psychiatric Genomics Consortium: ADHD Subgroup and Nancy J. Cox.

Kevin Jiang | newswise
Further information:
http://www.uchospitals.edu

Further reports about: ADHD Amphetamine Genetic Risk SNPs develop diseases dopamine drugs schizophrenia sensitivity variants

More articles from Life Sciences:

nachricht An evolutionary heads-up – The brain size advantage
22.05.2015 | Veterinärmedizinische Universität Wien

nachricht Endocrine disrupting chemicals in baby teethers
21.05.2015 | Goethe-Universität Frankfurt am Main

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Basel Physicists Develop Efficient Method of Signal Transmission from Nanocomponents

Physicists have developed an innovative method that could enable the efficient use of nanocomponents in electronic circuits. To achieve this, they have developed a layout in which a nanocomponent is connected to two electrical conductors, which uncouple the electrical signal in a highly efficient manner. The scientists at the Department of Physics and the Swiss Nanoscience Institute at the University of Basel have published their results in the scientific journal “Nature Communications” together with their colleagues from ETH Zurich.

Electronic components are becoming smaller and smaller. Components measuring just a few nanometers – the size of around ten atoms – are already being produced...

Im Focus: IoT-based Advanced Automobile Parking Navigation System

Development and implementation of an advanced automobile parking navigation platform for parking services

To fulfill the requirements of the industry, PolyU researchers developed the Advanced Automobile Parking Navigation Platform, which includes smart devices,...

Im Focus: First electrical car ferry in the world in operation in Norway now

  • Siemens delivers electric propulsion system and charging stations with lithium-ion batteries charged from hydro power
  • Ferry only uses 150 kilowatt hours (kWh) per route and reduces cost of fuel by 60 percent
  • Milestone on the road to operating emission-free ferries

The world's first electrical car and passenger ferry powered by batteries has entered service in Norway. The ferry only uses 150 kWh per route, which...

Im Focus: Into the ice – RV Polarstern opens the arctic season by setting course for Spitsbergen

On Tuesday, 19 May 2015 the research icebreaker Polarstern will leave its home port in Bremerhaven, setting a course for the Arctic. Led by Dr Ilka Peeken from the Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) a team of 53 researchers from 11 countries will investigate the effects of climate change in the Arctic, from the surface ice floes down to the seafloor.

RV Polarstern will enter the sea-ice zone north of Spitsbergen. Covering two shallow regions on their way to deeper waters, the scientists on board will focus...

Im Focus: Gel filled with nanosponges cleans up MRSA infections

Nanoengineers at the University of California, San Diego developed a gel filled with toxin-absorbing nanosponges that could lead to an effective treatment for skin and wound infections caused by MRSA (methicillin-resistant Staphylococcus aureus), an antibiotic-resistant bacteria. This "nanosponge-hydrogel" minimized the growth of skin lesions on mice infected with MRSA - without the use of antibiotics. The researchers recently published their findings online in Advanced Materials.

To make the nanosponge-hydrogel, the team mixed nanosponges, which are nanoparticles that absorb dangerous toxins produced by MRSA, E. coli and other...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International symposium: trends in spatial analysis and modelling for a more sustainable land use

20.05.2015 | Event News

15th conference of the International Association of Colloid and Interface Scientists

18.05.2015 | Event News

EHFG 2015: Securing health in Europe. Balancing priorities, sharing responsibilities

12.05.2015 | Event News

 
Latest News

Mesoporous Particles for the Development of Drug Delivery System Safe to Human Bodies

22.05.2015 | Materials Sciences

Computing at the Speed of Light

22.05.2015 | Information Technology

Development of Gold Nanoparticles That Control Osteogenic Differentiation of Stem Cells

22.05.2015 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>